Description

Eletriptan Hydrobromide (CAS 177834-92-3) is a high-purity pharmaceutical compound with the molecular formula C₂₂H₂₇BrN₂O₂S. This selective serotonin receptor agonist is widely recognized for its efficacy in the acute treatment of migraine headaches. As the hydrobromide salt of eletriptan, it offers enhanced solubility and bioavailability, making it a preferred choice for clinical and research applications. Our product is synthesized under strict GMP conditions, ensuring >99% HPLC purity and compliance with USP/EP standards. Available in milligram to kilogram quantities, this compound is ideal for pharmacological studies, reference standards, and formulation development. Each batch undergoes rigorous QC testing, including NMR, MS, and elemental analysis, to guarantee identity, potency, and safety.

Properties

• CAS Number: 177834-92-3
• Complexity: 582
• IUPAC Name: 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole;hydrobromide
• InChI: InChI=1S/C22H26N2O2S.BrH/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20;/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3;1H/t19-;/m1./s1
• InChI Key: UTINOWOSWSPFLJ-FSRHSHDFSA-N
• Exact Mass: 462.09766
• Molecular Formula: C22H27BrN2O2S
• Molecular Weight: 463.4
• SMILES: CN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4.Br
• Topological: 61.6
• Monoisotopic Mass: 462.09766
• Synonyms: Eletriptan hydrobromide, 177834-92-3, Eletriptan HBr, eletriptan monohydrobromide, UK 116044-04, UNII-M41W832TA3, CHEBI:61176, M41W832TA3, (R)-3-((1-Methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole monohydrobromide, NSC-759258, DTXSID001016113, NSC 759258, ELETRIPTAN HYDROBROMIDE (MART.), ELETRIPTAN HYDROBROMIDE [MART.], 3-(((R)-1-Methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)indole, monohydrobromide, 5-[2-(phenylsulfonyl)ethyl]-3-[(2R)-pyrrolidin-2-ylmethyl]-1H-indole hydrobromide, ELETRIPTAN HYDROBROMIDE (USP-RS), ELETRIPTAN HYDROBROMIDE [USP-RS], 1H-Indole, 3-(((2R)-1-methyl-2-pyrrolidinyl))methyl)-5-(2-(phenylsulfonyl)ethyl)-, monohydrobromide, 5-(2-(phenylsulfonyl)ethyl)-3-((2R)-pyrrolidin-2-ylmethyl)-1H-indole hydrobromide, 3-[[(R)-1-Methyl-2-pyrrolidinyl]methyl]-5-[2-(phenylsulfonyl)ethyl]indole, monohydrobromide, DTXCID101474255, 3-(1-methyl-2-pyrrolidinylmethyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole hydrobromide, (R)-3-(1-Methylpyrrolidin-2-ylmethyl)-5-(2-phenylsulfonylethyl)-1H-indole monohydrobromide, Relpax, (R)-3-((1-Methylpyrrolidin-2-yl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole hydrobromide, Eletriptan Hydrobromide [USAN], Eletriptan (hydrobromide), UK-116,044-04, 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indole;hydrobromide, 1H-Indole, 3-[[(2R)-1-methyl-2-pyrrolidinyl]methyl]-5-[2-(phenylsulfonyl)ethyl]-, hydrobromide (1:1), eletriptanhydrobromide, MFCD08141806, Relpax (TN), SCHEMBL317370, CHEMBL1201003, HY-A0010R, UTINOWOSWSPFLJ-FSRHSHDFSA-N, Eletriptan HBr – Bio-X trade mark, HY-A0010, Eletriptan hydrobromide (JAN/USAN), ELETRIPTAN HYDROBROMIDE [MI], Tox21_500408, Eletriptan (hydrobromide) (Standard), ELETRIPTAN HYDROBROMIDE [JAN], HB1775, s3180, AKOS024262728, AC-3398, BCP9000640, CCG-221712, CS-0379, FE38878, ELETRIPTAN HYDROBROMIDE [WHO-DD], NCGC00261093-01, BS-42146, FE162187, ELETRIPTAN HYDROBROMIDE [ORANGE BOOK], SW220149-1, D01973, Q27130865, 3-(N-methyl-2(R)-pyrrolidinyl methyl)-5-[2-(phenyl sulfonyl)ethyl]-1H-indole hydrobromide, 3-(N-Methyl-2(R)-pyrrolidinylmethyl)-5-(2-phenylsulphonylethly)-1H-indole hydrobromide, 3-(N-Methyl-2(R)-pyrrolidinylmethyl)-5-(2-phenylsulphonylethyl)-1H-indole hydrobromide, 3-(N-methyl-2(R)-pyrrolidinylmethyl)-5-[2-(phenyl sulfonyl)ethyl]-1H-indole hydrobromide, 3-{[1-Methylpyrrolidin-2(R)-yl]methyl}-5-(2-phenylsulphonylethyl)-1H-indole hydrobromide, (r)-3-[(1-methyl-2-pyrrolidinyl) methyl]-5-[2-(phenylsulfonyl) ethyl]-1h-indole monohydrobromide, 5-[2-(benzenesulfonyl)ethyl]-3-[[(2R)-1-methylpyrrolidin-2-yl]methyl]-1H-indol-1-ium;bromide

Eletriptan Hydrobromide is primarily used as an active pharmaceutical ingredient (API) in migraine therapeutics. It acts as a selective 5-HT_1B/1D receptor agonist, inducing cranial vasoconstriction and inhibiting neuropeptide release. Researchers utilize this compound for pharmacokinetic studies due to its rapid absorption and high oral bioavailability (~50%). In preclinical settings, it serves as a reference standard for investigating serotonin receptor mechanisms and vascular responses.

Safety and Hazards

GHS Hazard Statements

• H302 (47.2%): Harmful if swallowed [Warning Acute toxicity, oral]
• H318 (44.4%): Causes serious eye damage [Danger Serious eye damage/eye irritation]
• H319 (54.2%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
• H412 (44.4%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard]

Precautionary Statements

• P264, P264+P265, P270, P273, P280, P301+P317, P305+P351+P338, P305+P354+P338, P317, P330, P337+P317, and P501

Hazard Classes and Categories

• Acute Tox. 4 (47.2%)
• Eye Dam. 1 (44.4%)
• Eye Irrit. 2 (54.2%)
• Aquatic Chronic 3 (44.4%)

If you are interested or have any questions, please contact us at support@atomfair.com

Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.